Physician profile
Lina Soni
NPI 1649687963
$833.40
in general payments reported to CMS, 2019-2025
14 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2024: $137 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $275.92 | 2019 | |
| Medtronic, INC. | $123.05 | 2025 | Minimed 780g |
| Lilly USA, LLC | $98.15 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $69.81 | 2024-2025 | |
| Corcept Therapeutics | $50.63 | 2025 | Korlym |
| Novo Nordisk INC | $46.37 | 2025 | Wegovy, Ozempic |
| Abbott Laboratories | $24.13 | 2024 | Freestyle Libre 3 |
| Beta Bionics, INC. | $23.46 | 2024 | Ilet Bionic Pancreas |
| Grifols USA, LLC | $21.35 | 2025 | Xembify |
| Cequr Corporation | $21.03 | 2024 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $20.83 | 2025 | Yorvipath |
| Puma Biotechnology, INC. | $20.04 | 2024 | |
| Jazz Pharmaceuticals INC. | $19.62 | 2025 | |
| Amgen INC. | $19.01 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lina Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.